|17th February 2021||Randal W Scott||302,621||Conversion of derivative||$0.00|
|17th February 2021||Genetic Disorder L.P. Kkr||3,450,000||Open or private sale||$60.47||$208,617,360.00|
|17th February 2021||Randal W Scott||334,546||Conversion of derivative||$0.00|
|17th February 2021||Randal W Scott||312,500||Open or private purchase||$16.00||$5,000,000.00|
|17th February 2021||Randal W Scott||16,000||Open or private purchase||$62.50||$1,000,000.00|
|17th February 2021||Randal W Scott||752,897||Conversion of derivative||$0.00|
|13th January 2021||Uma Sinha||4,934||Open or private sale||$124.72||$615,362.07|
|13th January 2021||Uma Sinha||1,498||Open or private sale||$123.48||$184,971.09|
|13th January 2021||Uma Sinha||572||Open or private sale||$122.27||$69,936.55|
|13th January 2021||Uma Sinha||696||Open or private sale||$121.11||$84,292.14|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis.